⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ELDN News
Eledon Pharmaceuticals, Inc. Common Stock
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
globenewswire.com
ELDN
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
globenewswire.com
ELDN
Form 8-K
sec.gov
ELDN
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
ELDN
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
prnewswire.com
ELDN
VRTX
VKTX
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
prnewswire.com
SANA
ELDN
VRTX
NCEL
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
globenewswire.com
NCEL
ELDN
Form 8-K
sec.gov
ELDN
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
globenewswire.com
ELDN
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
globenewswire.com
ELDN